{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:36:21Z","timestamp":1772800581930,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"OptiNose US Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.clinthera.2019.09.013","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T09:16:37Z","timestamp":1573550197000},"page":"2343-2356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol"],"prefix":"10.1016","volume":"41","author":[{"given":"John C.","family":"Messina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot","family":"Offman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Carothers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramy A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.09.013_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jaci.2010.02.020","article-title":"Oral steroids and doxycycline: two different approaches to treat nasal polyps","volume":"125","author":"Van Zele","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.09.013_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/0003-4819-154-5-201103010-00003","article-title":"Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial","volume":"154","author":"Vaidyanathan","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.09.013_bib3","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2019.09.013_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2500\/ar.2016.7.0142","article-title":"Avascular necrosis after oral corticosteroids in otolaryngology: case report and review of the literature","volume":"7","author":"Kennedy","year":"2016","journal-title":"Allergy Rhinol (Providence)"},{"key":"10.1016\/j.clinthera.2019.09.013_bib5","first-page":"CD011993","article-title":"Different types of intranasal steroids for chronic rhinosinusitis","volume":"4","author":"Chong","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2019.09.013_bib6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1081-1206(10)63545-4","article-title":"Concerns about intranasal corticosteroids for over-the-counter use: position statement of the joint task force for the American academy of allergy, asthma, and immunology and the American college of allergy, asthma and immunology","volume":"96","author":"Bielory","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2019.09.013_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1398-9995.2000.00370.x","article-title":"Inhaled and nasal corticosteroids: safety aspects","volume":"55","author":"Passalacqua","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2019.09.013_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhino12.000","article-title":"European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"key":"10.1016\/j.clinthera.2019.09.013_bib9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00005537-200404000-00022","article-title":"Origin of nasal polyps: an endoscopic autopsy study","volume":"114","author":"Larsen","year":"2004","journal-title":"Laryngoscope"},{"key":"10.1016\/j.clinthera.2019.09.013_bib10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jamp.2011.0924","article-title":"Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump","volume":"25","author":"Djupesland","year":"2012","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.clinthera.2019.09.013_bib11","first-page":"69","article-title":"Videoendoscopic analysis of nasal steroid distribution","volume":"37","author":"Weber","year":"1999","journal-title":"Rhinology"},{"key":"10.1016\/j.clinthera.2019.09.013_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2500\/ajra.2014.28.4026","article-title":"Nasal deposition of ciclesonide nasal aerosol and mometasone aqueous nasal spray in allergic rhinitis patients","volume":"28","author":"Emanuel","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.clinthera.2019.09.013_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1089\/jamp.2014.1180","article-title":"Nasal deposition of HFA-beclomethasone, aqueous fluticasone propionate and aqueous mometasone furoate in allergic rhinitis patients","volume":"28","author":"Leach","year":"2015","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.clinthera.2019.09.013_bib14","series-title":"Flovent\u00ae HFA (Fluticasone Propionate) Inhalational Aerosol [package Insert]","year":"2014"},{"key":"10.1016\/j.clinthera.2019.09.013_bib15","series-title":"Flovent Diskus\u00ae (Fluticasone Propionate) Dry-Power Inhaler [package Insert]","year":"2019"},{"key":"10.1016\/j.clinthera.2019.09.013_bib16","first-page":"1","article-title":"Local and systemic safety of intranasal corticosteroids","volume":"22","author":"Sastre","year":"2012","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.09.013_bib17","series-title":"Flonase\u00ae (Fluticasone Propionate) Nasal Spray [package Insert]","year":"2011"},{"key":"10.1016\/j.clinthera.2019.09.013_bib18","series-title":"Flixonase\u00ae (Fluticasone Propionate) Nasule Drops [summary of Product Characteristics]","year":"2018"},{"key":"10.1016\/j.clinthera.2019.09.013_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.clinthera.2019.09.013_bib20","series-title":"Xhance\u00ae (Fluticasone Propionate) Exhalation Delivery System [prescribing Information]","year":"2017"},{"key":"10.1016\/j.clinthera.2019.09.013_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2273.2004.00797.x","article-title":"The assessment of topical nasal drug distribution","volume":"29","author":"Aggarwal","year":"2004","journal-title":"Clin Otolaryngol Allied Sci"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2019.09.013_bib22","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1089\/jam.2007.0569","article-title":"Devices for aerosol delivery to treat sinusitis","volume":"20","author":"Laube","year":"2007","journal-title":"J\u00a0Aerosol Med"},{"key":"10.1016\/j.clinthera.2019.09.013_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/thorax.56.3.186","article-title":"Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects","volume":"56","author":"Harrison","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.clinthera.2019.09.013_bib24","doi-asserted-by":"crossref","first-page":"AB253","DOI":"10.1016\/j.jaci.2016.12.815","article-title":"Intranasal fluticasone propionate delivered by exhalation delivery system (FLU-EDS) versus Flonase nasal spray and Flovent HFA: a randomized comparison of bioavailability","volume":"139","author":"Messina","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2019.09.013_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003088-200039001-00006","article-title":"Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma","volume":"39","author":"Daley-Yates","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2019.09.013_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0091-6749(98)70085-5","article-title":"Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis","volume":"102","author":"Vargas","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2019.09.013_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200039001-00007","article-title":"The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers","volume":"39","author":"Mackie","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2019.09.013_bib28","series-title":"Rhinocort Aqua (Budesonide) Nasal Spray [package Insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2019.09.013_bib29","series-title":"Beconase\u00ae AQ (Budesonide) Inhalational Aerosol [package Insert]","year":"2015"},{"key":"10.1016\/j.clinthera.2019.09.013_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.09.013_bib31","first-page":"103","article-title":"Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations","volume":"51","author":"Daley-Yates","year":"2001","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.013_bib32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4065\/79.4.458","article-title":"Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial","volume":"79","author":"Kemp","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2019.09.013_bib33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0091-6749(99)70180-6","article-title":"Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma","volume":"103","author":"Li","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2019.09.013_bib34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/head.12167","article-title":"Improved pharmacokinetics of sumatriptan with Breath Powered nasal delivery of sumatriptan powder","volume":"53","author":"Obaidi","year":"2013","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2019.09.013_bib35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and histological factors affecting intranasal drug and vaccine delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr Drug Deliv"},{"issue":"1","key":"10.1016\/j.clinthera.2019.09.013_bib36","first-page":"103","article-title":"Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations","volume":"51","author":"Daley-Yates","year":"2001","journal-title":"Br J Clin\u00a0Pharmacol"},{"issue":"4","key":"10.1016\/j.clinthera.2019.09.013_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2125.2007.02856.x","article-title":"Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction","volume":"64","author":"Mortimer","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.clinthera.2019.09.013_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2310\/7750.2008.07029","article-title":"Side effects of short-term oral corticosteroids","volume":"12","author":"Richards","year":"2008","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.clinthera.2019.09.013_bib39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.otc.2010.04.003","article-title":"A comprehensive review of the adverse effects of systemic corticosteroids","volume":"43","author":"Poetker","year":"2010","journal-title":"Otolaryngol Clin North Am"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2019.09.013_bib40","first-page":"S22","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819304916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819304916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:54Z","timestamp":1758963054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819304916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0149291819304916"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}